Beyond semaglutide and tirzepatide, where might we find the next GLP 1 based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and Clinical trials of subcutaneous tirzepatide, retatrutide, and Download Scientific Diagram Cagrilintide, an amylin analogue, is a promising medication for weight loss by enhancing satiety, delaying gastric emptying, and suppressing appetite. In my patients, I have also seen increased In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results